medigraphic.com

2011, Number 1

<< Back Next >>

Rev Hematol Mex 2011; 12 (1)

Valganciclovir for the prophylaxis of cytomegalovirus infection early after allogenic stem cell transplantation

Bachier C, PaShaughnessy P, Grimley M, Carrum G, Freytes CO, Callander N, Walsh T, LeMaistre CF

Language: English
References: 26
Page: 23-27
PDF size: 70.69 Kb.


ABSTRACT

Despite improvements in methods for the early diagnosis of Cytomegalovirus (CMV) infection, 5% of allogeneic stem cell transplant patients receiving preemptive therapy develop CMV disease. In addition, the use of highly immunosuppressive and the use of mismatched donors have increased the incidence of CMV infection and disease. Thirty CMV seropositive patients participated in a prospective trial evaluating the safety and efficacy of oral valganciclovir administered at 900 mg daily 5 days a week starting 21 to 35 days after transplant and continuing through Day 100 post transplant. Twenty-four of 30 (80%) patients had other risk factors for the development of CMV infection including: use of alemtuzumab (n=9), corticosteroid therapy for treatment of graft versus host disease (n=12), or unrelated donor transplant (n=12). Patients were monitored with weekly quantitative CMV PCR analysis at a central lab. Five patients developed myeloid toxicity related to valganciclovir (absolute neutrophil count ‹ 1,000/µL = 1, platelets ‹ 50,000/µL = 4). CMV infection occurred in 4 patients with no CMV disease in any of the patients. We conclude that valganciclovir at the dose used in this study is well tolerated with minimal, reversible myelosuppression. The incidence of CMV infection with valganciclovir prophylaxis was low in this high-risk group.


REFERENCES

  1. Prentice HG and Kho P. Clinical strategies for the Management of Cytomegalovirus infection and Disease in Allogeneic Bone Marrow Transplant. BMT 1997;19:135-142.

  2. Goodrich JM, Mori M, Gleaves CA, et al. Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation. N Engl J Med 1991;325:1601-1607.

  3. Ljungman P, Aschan J, Lewensohn-Fuchs A, et al. Results of Different Strategies for Reducing Cytomegalovirus-Associated Mortality in Allogeneic Stem Cell Transplant Recipients. Transplantation 1998;66:1330-1334.

  4. Broers AEC, van der Holt R, van Esser JWJ, et al. Increased transplant-related morbidity and mortality in cmv - seropositve patients despite highly effective prevention of CMV disease after allogeneic t-cell-depleted stem cell transplantation. Blood 2000;95:2240-2245.

  5. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Int Med 1993;118:173-178.

  6. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Int Med 1993;118:179-184.

  7. Salzberger B, Bowden RA, Hackman RC, et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997;90:2502-2508.

  8. Boeckh M, Zaia JA, Jung D, et al. A study of the pharmacokinetics, antiviral activity and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Bio Blood and Marrow Transplantation 1998;4:13-19.

  9. Avery RK, Adal KA, Longworth DL, et al. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and preemptive therapy. Bone Marrow Transplantation 2000; 26, 763-767.

  10. Moretti S, Zikos P, Van Lint MT, et al. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hematopoietic stem cell transplantation (HSCT): a randomized study. Bone Marrow Transplant. 1998; 22:179-180.

  11. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99:1159-1164.

  12. Junghanss C, Storb R, Maris M, et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.

  13. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after non myeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-4363.

  14. Hakki M, Riddell S, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003;102:3060-306.

  15. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811-2815.

  16. Einsele H, Reusser P, Hebart H, et al. Pharmakokinetics of valganciclovir after AlloSCT: A fixed oral dose can be used for preemptive therapy in patients with normal body weight-even with intestinal GVHD. Blood (ASH Annual Meeting Abstract, Nov 2004; 104, 2239.

  17. Winston DJ, Ratanatharathorn V, Lindsey B, et al. Pharmacokinetics of ganciclovir following oral valganciclovir versus intravenous ganciclovir in allogeneic hematopoietic stem cell transplant patients with stable graft versus host disease of gastrointestinal tract. Blood (ASH Annual Meeting Abstract, Nov 2004; 104, 2223.

  18. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.

  19. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:3002-3008.

  20. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407-414.

  21. Einsele H, Hebart, Kaufffman-Schneider, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25:757-763.

  22. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow recipients. Clin Infect Dis 1999;28:618-623.

  23. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus lead, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998;21:597-605.

  24. Winston DJ, Yeager AM, Chandrasekar PH, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36:749-758.

  25. Ljungman P, de La Camera R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplant. Blood 2002;99:3050-3056.

  26. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft versus host disease. Blood 1986;67:1162-1167.




2020     |     www.medigraphic.com